The company made the announcement after a new round of research results bolstered the case for the experimental medicine, which may ultimately compete against Dupixent and Ebglyss.
An article from
Dive Brief
The company made the announcement after a new round of research results bolstered the case for the experimental medicine.
Published May 27, 2026
By
Apogee Therapeutics secures up to $800 million royalty deal with Blackstone Life Sciences to fund Phase 3 trials of eczema drug…
Apogee shares fell after announcing a $1.3 billion Blackstone financing deal alongside positive Phase 2 eczema drug results.
Shares in biotechnology company Apogee Therapeutics (APGE) are set to start the new week off in great shape on reports that it…
Il finanziamento è per lo sviluppo di zumilokibart, potenziale rivale di Dupixent, farmaco sviluppato da Regeneron…
Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis
AbbVie’s largest deal in more than half a decade adds a group of immune disease medications — among them a Dupixent…
Apogee lands Blackstone $800M royalty deal to move Dupixent rival toward Phase 3
Apogee Stock Slides After Blackstone Financing Deal And Positive Drug Data - Apogee Therapeutics (NASDAQ:
Blackstone scommette su Apogee Therapeutics fino a 1,3 miliardi
ASCO: After Takeda’s defeat, Dizal picks up baton to take on J&J in EGFR lung cancer subtype
ASCO preview: With expectations jacked up, Akeso's ivonescimab to face scrutiny in high-stakes plenary
ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%
